{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:34:21Z","timestamp":1768286061646,"version":"3.49.0"},"reference-count":30,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:sec>\n<jats:title>Object<\/jats:title>\n<jats:p>Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide. A combination of carmustine wafers with the Stupp treatment regimen has only been investigated in retrospective studies.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In a single-institution prospective study, the authors assessed 12-month progression-free survival (PFS), toxicity, and overall survival in patients with glioblastoma treated with surgery, carmustine wafers, radiotherapy, and 6-month metronomic temozolomide chemotherapy. Thirty-five patients with de novo glioblastoma, between the ages of 18 and 70 years, and with Karnofsky Performance Scale scores of at least 70, were included in the study. Patients were followed monthly and assessed using MRI every 2 months.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After a median follow-up of 15 months, the median time to tumor progression was 12.5 months and median survival was 17.8 months. Due to toxicity (mostly hematological), 7 patients had to prematurely stop temozolomide treatment. Twenty-two patients developed Grade 3 CD4<jats:sup>+<\/jats:sup> lymphocytopenia. Three patients developed oral-esophageal candidiasis, 2 developed pneumonia, and 1 developed a dorsolumbar zoster. Early intracranial hypertension was observed in 1 patient, and 1 was treated empirically for suspected brain abscess. One patient died of <jats:italic>Legionella<\/jats:italic> pneumonia soon after repeat surgery.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Overall, this treatment schedule produced promising results in terms of PFS without a marked increase in toxicities as compared with the Stupp regimen. However, the gain in median survival using this schedule was less clear. Only prospective comparative trials will determine whether these preliminary results will translate into a long-term survival advantage with an acceptable toxicity profile.<\/jats:p><\/jats:sec>","DOI":"10.3171\/2012.12.jns111893","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T15:02:45Z","timestamp":1359126165000},"page":"821-829","source":"Crossref","is-referenced-by-count":26,"title":["Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results"],"prefix":"10.3171","volume":"118","author":[{"given":"Andrea","family":"Salmaggi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Milanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Silvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Gaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fariselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Lazzaro","family":"Solero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Maccagnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Casali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Guzzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Pollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Ciusani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"DiMeco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"key":"b1-jns111893","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1002\/cncr.24398","article-title":"Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy","volume":"115","author":"Affronti","year":"2009"},{"key":"b2-jns111893","series-title":"Med Pediatr Oncol","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/(SICI)1096-911X(199801)30:1<40::AID-MPO11>3.0.CO;2-C","article-title":"CD4+ T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers","volume":"30","author":"Azuma","year":"1998"},{"key":"b3-jns111893","series-title":"Neurosurg Rev","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10143-010-0280-7","article-title":"First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience","volume":"33","author":"Bock","year":"2010"},{"key":"b4-jns111893","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995"},{"key":"b5-jns111893","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11060-010-0251-4","article-title":"Radiographic patterns of relapse in glioblastoma","volume":"101","author":"Chamberlain","year":"2011"},{"key":"b6-jns111893","series-title":"Br J Neurosurg","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/02688697.2010.550342","article-title":"The sequential use of carmustine wafers (Gliadel\u00ae) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review","volume":"25","author":"Dixit","year":"2011"},{"key":"b7-jns111893","series-title":"Cancer Immunol Immunother","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00262-006-0236-5","article-title":"T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005","volume":"56","author":"Ersvaer","year":"2007"},{"key":"b8-jns111893","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009"},{"key":"b9-jns111893","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2006","article-title":"RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (tmz) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)","author":"Gilbert","year":"2011"},{"key":"b10-jns111893","series-title":"Nat Rev Cancer","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004"},{"key":"b11-jns111893","series-title":"Curr Med Res Opin","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1185\/03007990802611935","article-title":"Localized BCNU chemotherapy and the multimodal management of malignant glioma","volume":"25","author":"La Rocca","year":"2009"},{"key":"b12-jns111893","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990"},{"key":"b13-jns111893","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review","volume":"89","author":"Marras","year":"2000"},{"key":"b14-jns111893","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3171\/2008.5.17557","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. Clinical article","volume":"110","author":"McGirt","year":"2009"},{"key":"b15-jns111893","series-title":"Ann Surg Oncol","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1245\/s10434-010-1081-5","article-title":"Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience","volume":"17","author":"Menei","year":"2010"},{"key":"b16-jns111893","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.25035","article-title":"Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects","volume":"116","author":"Neyns","year":"2010"},{"key":"b17-jns111893","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ijrobp.2010.11.073","article-title":"Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after intial surgery in patients with newly diagnosed high-grade gliomas","volume":"82","author":"No\u00ebl","year":"2012"},{"key":"b18-jns111893","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2008"},{"key":"b19-jns111893","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11060-008-9576-7","article-title":"A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients","volume":"88","author":"Pan","year":"2008"},{"issue":"Suppl","key":"b20-jns111893","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"13003","DOI":"10.1200\/jco.2008.26.15_suppl.13003","article-title":"Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide","volume":"26","author":"Ryken","year":"2008"},{"key":"b21-jns111893","series-title":"J Neurosurg Sci","first-page":"1","article-title":"Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis","volume":"55","author":"Salvati","year":"2011"},{"key":"b22-jns111893","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma","volume":"13","author":"Sampson","year":"2011"},{"key":"b23-jns111893","series-title":"Control Clin Trials","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989"},{"key":"b24-jns111893","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(02)08091-1","article-title":"Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials","volume":"359","author":"Stewart","year":"2002"},{"key":"b25-jns111893","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005"},{"key":"b26-jns111893","series-title":"Electrophoresis","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.0.CO;2-4","article-title":"Quantitative DNA methylation analysis by fluorescent polymerase chain reaction single-strand conformation polymorphism using an automated DNA sequencer","volume":"21","author":"Suzuki","year":"2000"},{"key":"b27-jns111893","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-010-0750-6","article-title":"Molecular diagnostics of gliomas: the clinical perspective","volume":"120","author":"Tabatabai","year":"2010"},{"key":"b28-jns111893","series-title":"Br J Cancer","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003"},{"key":"b29-jns111893","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007"},{"key":"b30-jns111893","series-title":"Neuro Oncol","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/118\/4\/article-p821.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/118\/4\/article-p821.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/118\/4\/article-p821.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:43:40Z","timestamp":1660499020000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/118\/4\/article-p821.xml"}},"subtitle":["Clinical article"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":30,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2012.12.jns111893","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}